Hematology and Oncology | James Thomas, MD, PhD | Professor

James P. Thomas, MD, PhD

Professor, Medicine (Hematology/Oncology); Secondary Faculty

Contact Information

Education

PhD, Biochemistry, Medical College of Wisconsin, 1989
MD, Medical College of Wisconsin, 1991

Biography

James Thomas, MD, PhD, joined the faculty at the Medical College of Wisconsin in the Division of Hematology and Oncology in September of 2010. Dr. Thomas received his PhD in Biochemistry and his MD from the Medical College of Wisconsin. He completed his residency training in internal medicine at the Medical College of Wisconsin and subsequently completed a fellowship in Medical Oncology at the University of Wisconsin. Dr. Thomas joined the faculty at the University of Wisconsin and was the Disease Leader for Gastrointestinal Cancers. Dr. Thomas served as the Medical Director of the Clinical Trials Office of the Ohio State Comprehensive Cancer Center and was on the NCCN Panel for Colorectal Cancers. He is the Chair of the American Association of Cancer Institutes Clinical Research Group. Dr. Thomas has published over 70 peer reviewed articles.

Research Interests

His research interests are in oncology drug development and in the treatment of gastrointestinal cancers. Dr. Thomas has a long standing research effort in the role of reactive oxygen species in cancer development and treatment.

A Comprehensive Program for the Enhancement of Accrual to Clinical Trials.

(Porter M, Ramaswamy B, Beisler K, Neki P, Single N, Thomas J, Hofacker J, Caligiuri M, Carson WE 3rd.) Ann Surg Oncol. 2016 07;23(7):2146-52.
p38γ MAPK is required for inflammation-associated colon tumorigenesis.

(Yin N, Qi X, Tsai S, Lu Y, Basir Z, Oshima K, Thomas JP, Myers CR, Stoner G, Chen G.) Oncogene. 2016 Feb 25;35(8):1039-48.
Chemotherapy for Surgically Resected Intrahepatic Cholangiocarcinoma.

(Miura JT, Johnston FM, Tsai S, George B, Thomas J, Eastwood D, Banerjee A, Christians KK, Turaga KK, Pawlik TM, Clark Gamblin T.) Ann Surg Oncol. 2015 Oct;22(11):3716-23.
Diagnostic laparoscopy should be performed before definitive resection for pancreatic cancer: a financial argument.

(Jayakrishnan TT, Nadeem H, Groeschl RT, George B, Thomas JP, Ritch PS, Christians KK, Tsai S, Evans DB, Pappas SG, Gamblin TC, Turaga KK.) HPB (Oxford). 2015 Feb;17(2):131-9.
Comparative Effectiveness of Hepatic Artery Based Therapies for Unresectable Colorectal Liver Metastases: A Meta-Analysis.

(Zacharias AJ, Jayakrishnan TT, Rajeev R, Rilling WS, Thomas JP, George B, Johnston FM, Gamblin TC, Turaga KK.) PLoS One. 2015;10(10):e0139940.
Tumor profiling of gastric and esophageal carcinoma reveal different treatment options.

(Miura JT, Xiu J, Thomas J, George B, Carron BR, Tsai S, Johnston FM, Turaga KK, Gamblin TC.) Cancer Biol Ther. 2015;16(5):764-9.
Molecular profiling in gastric cancer: examining potential targets for chemotherapy.

(Miura JT, Johnston FM, Thomas J, George B, Eastwood D, Tsai S, Christians KK, Turaga KK, Gamblin TC.) J Surg Oncol. 2014 Sep;110(3):302-6.
Systematic review of outcomes of patients undergoing resection for colorectal liver metastases in the setting of extra hepatic disease.

(Hwang M, Jayakrishnan TT, Green DE, George B, Thomas JP, Groeschl RT, Erickson B, Pappas SG, Gamblin TC, Turaga KK.) Eur J Cancer. 2014 Jul;50(10):1747-1757.
Management of acute cholecystitis in cancer patients: a comparative effectiveness approach.

(Jayakrishnan TT, Groeschl RT, George B, Thomas JP, Pappas S, Gamblin TC, Turaga KK.) Surg Endosc. 2014 May;28(5):1505-14.
Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?

(Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, Wiebe L, Kelly T, Erickson B, Wang H, Evans DB, George B.) Oncologist. 2014 Mar;19(3):266-74.
5-FU/leucovorin, uifinotecan, oxaliplatin (FOLFIRINOX)induction followed by chemoXRT in borderline resectable pancreatic cancer.

(Jordan Kharofa, Tracy R. Kelly, Paul S. Ritch, Ben George, Lauren Allison Wiebe, James P. Thomas, Kathleen K. Christians, Douglas B. Evans, Beth Erickson .) Journal of Clinical Oncology . 10.1200/jco.2012.30.15_suppl.e1461 Journal of Clinical Oncology 30, no. 15_suppl -published online before print.
PB-42: Design and characterization of a glutathione pro-drug selectively delivered to normal tissue and not tumor tissue

(Thomas JP, Geiger PG.) Cancer Res. Thomas JP, Geiger PG. Abstract 4443: PB-42: Design and characterization of a glutathione pro-drug selectively delivered to normal tissue and not tumor tissue. Cancer Res. August 1, 2015 75; 4443. .

James Thomas, MD, PhD